Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 9/2010

01-09-2010 | Original Article

Acrylamine-induced autoimmune phenomena

Author: Bruce Rothschild

Published in: Clinical Rheumatology | Issue 9/2010

Login to get access

Abstract

The objective of this study is to document a series of cases of occupationally derived autoimmune disease. Individuals with occupational exposure to acrylamides were evaluated clinically and biochemically/immunologically for evidence of autoimmune disease. Symptoms and signs and immuno-reactivity were monitored during exposure-free and re-exposure as part of the individuals’ clinical evaluation. Six individuals with occupational acrylamide exposure had clinical and laboratory alterations characteristic of drug-induced autoimmune disease, specifically lupus, anti-phospholipid syndrome, Sjogren’s syndrome, scleroderma, and polymyositis. The similarity of the full spectrum of disease in the reported patients to that found with procainamide strongly suggests the effects of occupational exposure. This uncontrolled study suggests the need for a full epidemiologic analysis of all individuals working with such occupational exposure, including full clinical and immunological examination.
Literature
1.
Boltzer JW (1983) Systemic lupus erythematosus. I. Historical aspects. Maryland State Med J 37:439
2.
Lahita RG (1987) Introduction. In: Lahita RG (ed) Systemic lupus erythematosus. Wiley, New York, pp 1–3
3.
Smith CD, Cyr M (1988) The history of lupus erythematosus from Hippocrates to Osler. Rheumat Dis Clin N Amer 14:1
4.
Talbott JH (1987) Historical background of discoid and systemic lupus erythematosus. In: Wallace DL, Dubois EL (eds) Lupus erythematosus. Lea & Febiger, Philadelphia, pp 3–11
5.
Hoffman BJ (1945) Sensitivity of sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph 51:190–192
6.
Ladd AT (1962) Procainamide-induced lupus erythematosus. N Engl J Med 267:1357–1358PubMed
7.
Hargraves MM, Richmond H, Morton R (1948) Presentation of two bone marrow elements: the tart cell and the LE cell. Proc Staff Meet Mayo Clin 23:25
8.
Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243–249CrossRefPubMed
9.
Yung R, Richardson B (2002) Drug-induced rheumatic syndromes. Bull Rheum Dis 51(4):1–4
10.
Yung RL, Richardson BC (1994) Drug-induced lupus. Rheumatic Dis Clin N Amer 20:61–86
11.
DeRoos AJ, Cooper GS, Alavanja MC, Sandler DP (2005) Rheumatoid arthritis among women in the agricultural health study: risk associated with farming activities and exposures. Ann Epidemiol 15:762–770CrossRef
12.
Gold LS, Ward MH, Dosemeci M, DeRoos AJ (2007) Systemic autoimmune disease mortality and occupational exposures. Arthritis Rheum 56:3189–3201CrossRefPubMed
13.
Sawalha AH, Richardson BC (2007) The environment in the pathogenesis of systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS, eds. Systemic lupus erythematosus: a companion to rheumatology. Mosby/Elsevier, pp 64-73
14.
Gourley M, Miller FW (2007) Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 3:172–179CrossRefPubMed
15.
Lossaso L, Rapport LJ, Axelrod BN (2001) Neuropsycholgical symptoms associated with low-level exposure to solvent and (Meth)acrylates among nail technicians. Neuropsych Neuropsych Behav Neurol 14:183–189
16.
Lundberg I, Alfredsson L, Plato N, Sverdrup B, Klareskog L, Kleinau S (2004) Occupation, occupational exposure to chemicals and rheumatological disease: a register-based cohort study. Scand J Rheumatol 23:305–310CrossRef
17.
DeBandt M, Sibilia J, Le Loëët X, Poruzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation (2004) Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545–R551CrossRef
18.
19.
Murry JM, Butler JR (1988) Neuropsychological dysfunctioning associated with the dental office environment. Intl J Biosoc Res 10:45–68
20.
Haddad FS, Cobb AG, Bentley G, Levell NJ, Dowd PM (1996) Hypersensitivity in aseptic loosening of total hip replacements. J Bone Joint Surg 78B:546–549
21.
Linder L (1976) Tissue reaction to methyl methacrylate monomer. Acta Orthopaed Scand 47:3–10CrossRef
22.
Potter JL, Krill CE Jr, Neal D, Kofron WG (1988) Methemoglobinemia due to ingestion of N, N-dimethyl-p-toluidine, a component used in the fabrication of artificial nails. Ann Emerg Med 17:161–163CrossRef
23.
Stea S, Granchi D, Zolezzi C, Ciapetti G, Visentin M, Cavedagna D, Pizzoferrato A (1997) High-performance liquid chromatography assay of N, N-dimethyl- = p-toluidine released from bone cements: evidence for toxicity. Biomaterials 18:243–246CrossRefPubMed
24.
Taningher M, Pasquini R, Bonatti S (1993) Genotoxicity analysis of N, N-dimethylaniline and N, N-dimethyl-p-toluidine. Environ Mol Mutagen 21:349–356CrossRefPubMed
25.
Tesk JA, Antonucci JM, Eichmiller FC, Kelly JR, Rupp NW, Waterstrat RW, Fraker AC, Chow LC, George LA, Stanbury JW, Parry EE (1993) Dental materials. In: Kroschwitz JI, Howe-Grant M (eds) Kirk-Othmer encyclopedia of chemical technology, 4th edn. New York: Wiley 7:946-1022
26.
Tosti A, Bardazzi F, Piancastelli E, Brasile GP (1990) Contact stomatitis due to N, N-dimethyl-para-toluidine. Contact Dermat 22:113CrossRef
27.
Rubin RL, Waqa S (1987) Antihistone antibodies in systemic lupus erythematosus. J Rheumatol 13S:118–126
28.
Niakan E, Bertorini TE, Acchiardo SR, Werner MF (1981) Procainamide-induced myasthenia-like weakness in a patient with peripheral neuropathy. Arch Neurol 38:378–379PubMed
29.
Pasha SF, Pruthi RK (2006) Procainamide-induced pure red cell aplasia. Intl J Cardiol 110:125–126CrossRef
30.
Burlingame RW, Boey ML, Starkebaum G, Rubin RL (1994) The central role of chromatin in the autoimmune response to histones and DNA in systemic lupus erythematosus. J Clin Invest 94:184–192CrossRefPubMed
31.
Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidem Biomark Prevent 9:905–910
32.
Rothman N, Stewart WF, Caporaso NE, Hayes RB (1993) Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidem Biomark Preven 2:299–303
33.
Zhu Y, Hein DW, Doll MA, Reynolds KK, Abudu N, Valdes R Jr, Linder MW (2006) Simultaneous determination of 7 N-acetyltransferase-2 sequence variations by allele-specific primer extension assay. Clin Chem 52:1–7CrossRef
34.
Deitz AC, Rothman N, Rebbeck TR, Hayes RB, Chow W-H, Zheng W, Hein DW, Garcia-Closas M (2004) Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2(NAT2), smoking, and bladder cancer. Cancer Epidem Biomark Preven 13:1543–1546
35.
Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29:2492–2499PubMed
36.
Reidenberg MM (1983) Aromatic amines and the pathogenesis of lupus erythematosus. Amer J Med 75:1037–1042CrossRefPubMed
37.
Stringer GC, Hunter SW, Bonnabeau RC Jr (1977) Hypersensitivity pneumonitis following prolonged inhalation of hair spray. Thesaurosis JAMA 238:888–889CrossRef
38.
Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M (2007) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNF alpha-blocking agents in rheumatoid arthritis. Clin Rheumatol 26:91–95CrossRef
39.
Aryal BK, Khuder SA, Schaum A (2001) Meta-analysis of systemic sclerosis and exposure to solvents. Amer J Indust Med 40:271–274CrossRef
40.
Kettaneh A, Al Moufti O, Tiev KP, Chayet C, Toledano C, Fabre B, Fardet L, Cabane J (2007) Occupational exposure to solvents and gender related risk of systemic sclerosis: a meta-analysis of case-control studies. J Rheumatol 34:97–103PubMed
41.
Maitre A, Houra M, Bonneterre V, Arslan MT, Bergeret A, de Gaudemaris R, Carpentier P (2004) Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 31:2395–2401PubMed
42.
Phelps RG, Fleishmajer R (1988) Clinical, pathologic, and immunopathologic manifestations of the toxic oil syndrome: analysis of fourteen cases. J Amer Acad Dermatol 18:313–324CrossRef
43.
44.
Khan MF, Kaphalia BS, Prabhakar BS, Kanz MF, Ansari GA (1995) Tricholorethene-induced autoimmune response in female MRL+/+ mice. Toxicol Appl Pharmacol 134:155–160CrossRefPubMed
45.
Bing RF, Russell GI, Thurston H, Swales JO (1980) Hydralazine in hypertension: is there a safe dose? Brit Med J 281:353–354CrossRefPubMed
46.
Harland SJ, Facchini V, Timbrell JA (1980) Hydralazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype. Brit Med J 281:273–274CrossRefPubMed
47.
Henningsen NC, Cederberg A, Hanson A, Johansson BW (1978) Effects of long-term treatment with procainamide. Acta Med Scand 198:475–482
48.
Perry HM Jr (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Amer J Med 54:58–71CrossRefPubMed
49.
Uetrecht JP, Woosley RL (1981) Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 6:118–134CrossRefPubMed
50.
Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298:1157–1159PubMed
51.
Goebel C, Vogel C, Wulferink M, Mittmann S, Sachs B, Scharaa S, Abel J, Degen G, Uetrecht J, Gleichmann E (1999) Procainamide, a drug causing lupus, induces prostaglanding H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. Chem Res Toxicol 12:488–500CrossRefPubMed
52.
Hein DW, Weber WW (2002) Metabolism of procainamide, hydralazine and isoniazid in relation to autoimmune reactions. In: Kammuller ME, Bloksma N, Seinen W (eds) Autoimmunity and toxicology: immune disregulation induced by drugs and chemicals. Elsevier Science Publishers, New York, pp 239–265
53.
Rubin RL, Curnutte JT (1989) Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro. J Clin Invest 83:1336–1343CrossRefPubMed
54.
Uetrecht JP (1985) Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 232:420–425PubMed
55.
Carter JD, Valeriano-Marcet J, Kanik KS, Vasey FB (2001) Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. South Med J 94:1122–1123PubMed
56.
Rothschild BM, Verrier Jones J, Chesney C, Pifer DD, Thompson LD, James KK, Badger H (1983) Relationship of clinical findings in systemic lupus erythematosus to seroreactivity. Arthritis Rheum 26:45–51CrossRefPubMed
57.
Carlson E, Rothfield N (2003) Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 48:1165–1166CrossRefPubMed
58.
Olson NJ (2004) Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 18:677–688CrossRef
59.
Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, Andrassy K (2007) Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 36:291–298CrossRefPubMed
60.
Burlingame RW, Rubin RL (1996) Autoantibody to the nucleosome subunit (H2a-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions. Mol Biol Rep 23:159–166CrossRefPubMed
61.
Clayton AL, Hazzalin CA, Mahadevan LC (2006) Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 23:289–296CrossRefPubMed
62.
Elsharkawy AM (2007) Todralazine hepatotoxicity: a sting in the histone tail. J Hepatol 46:189–192CrossRefPubMed
63.
Dieker JW, Fransen JH, van Bavel CC, Briand J-P, Jacobs CW, Muller S, Berden JH, van der Vlag J (2007) Aptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 56:1921–1933CrossRefPubMed
64.
Callskan R, Masatlioglu S, Aslan M, Altun M, Saribas S, Ergin S, Uckan E, Koksal V, Oz V, Altas K, Fresko I, Kocazeybek B (2005) The relationship between arthritis and human parvovirus B19 infection. Rheumatol Intl 26:7–11CrossRef
65.
Quddus J, Johnson KJ, Galvalchin J, Amento EP, Chrisp CE, Yung RL, Richardson BC (1993) Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-Azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92:38–53CrossRefPubMed
66.
Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey A-B (1997) High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 24:1083–1088PubMed
67.
Hughes GR (2003) Migraine, memory loss, and ‘multiple sclerosis’. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J 79:81–83CrossRefPubMed
68.
Dean JH, Murray MJ (1991) Toxic responses to the immune system. In: Amdur M, Doull J, Klaassen CD (eds) Casarett and Doull’s toxicology. Pergamon Press, New York, pp 282–333
69.
Kravitz RL, Duan N, White RH (2008) N-of-1 trials of expensive biological therapies. Arch Intern Med 168:1028–1033CrossRef
70.
Gladman D, Chalmers A, Urowitz MB (1997) Serologically negative systemic lupus erythematosus. XIV International Congress of Rheumatology, San Francisco. 1997:186
71.
Alshekaili J, Li C, Cook MC (2010) Heterophile interference accounts for method-specific dsDNA antibodies in patients receiving anti-TNF treatment. Rheumatology 49:891–897CrossRefPubMed
72.
Laroche M, Brouchet A, Mazières B (2009) Multifocal bone infarcts and buprenorphine: association or coincidence? J Rheumatol 36:2369–2370CrossRefPubMed
73.
Slimani S, Ben Ammar A, Ladjouze-Rezig A (2010) Connective tissue diseases after heavy exposure to silica: a report of nine cases in stonemasons. Clin Rheumatol 28. doi:10.​1007/​s10067-009-1371-0
Metadata
Title
Acrylamine-induced autoimmune phenomena
Author
Bruce Rothschild
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1513-4

Other articles of this Issue 9/2010

Clinical Rheumatology 9/2010 Go to the issue

Original Article

Quality of life and satisfaction with life in SLE patients—the importance of clinical manifestations

Brief Report

Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis

OriginalPaper

A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis

Case Report

Fungal arthritis of the knee caused by Mycoleptodiscus indicus

Original Article

Pelvic MRI findings of juvenile-onset ankylosing spondylitis

Letter to Editor

Analysis on the infection among patients with nephrotic syndromes and systemic vasculitis treated with mycophenolate mofetil
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits